Research feed
Recently published diabetes studies added to Dediabetes, summarized and organized by intervention and outcome.
Sorted by publication date. Some studies may have been added to Dediabetes later.
This study evaluated a health literacy-adapted educational intervention for patients with Type 2 Diabetes Mellitus, finding significant improvements in various health metrics.
This study evaluated the effects of an empowerment-based interprofessional follow-up intervention on individuals with Type 2 diabetes, finding significant improvements in glycemic control, body weight, and waist circumference.
This study evaluated the effects of Berberine Ursodeoxycholate (HTD1801) on type 2 diabetes management. Results indicated significant reductions in HbA1c and fasting plasma glucose levels.
This study evaluated the efficacy and safety of lobeglitazone as an add-on therapy for patients with type 2 diabetes inadequately controlled with metformin and empagliflozin, finding significant improvements in HbA1c levels.
This study examined the impact of magnesium deficiency on diabetes and its complications, finding significant reductions in serum calcium, urinary magnesium, cholesterol, and LDL cholesterol levels with simvastatin treatment.
This study evaluated the effectiveness of the Rama Diabetes Care app for managing uncontrolled Type 2 diabetes in adults. While some improvements were noted, not all findings were statistically significant.
A structured lifestyle intervention improved eating self-efficacy in patients with type 2 diabetes, particularly through the Transcultural Diabetes Nutrition Algorithm with Motivational Interviewing.
This study evaluated the effects of qigong and tai chi on middle-aged and older adults with type 2 diabetes mellitus (T2DM). Tai chi significantly increased HbA1C levels and reduced C-Peptide levels compared to the control group.
This study evaluated the efficacy and safety of tirzepatide in Korean patients with type 2 diabetes, showing significant reductions in HbA1c and body weight.
This study evaluated the efficacy and safety of imeglimin as an add-on therapy to DPP-4 inhibitors in patients with type 2 diabetes, showing mixed results in glycemic control.
Latest Evidence
Build your workspace to keep track of the latest diabetes research.
